Insights

Strategic partnerships Royal Biologics has recently formed a strategic partnership with Jellagen, signaling openness to collaboration with complementary biotech players. This suggests potential sales opportunities through co-developed products, bundled solutions, or channel partnerships that leverage both companies’ strengths.

Wound care expansion With the launch of Derm-Maxx and the establishment of a dedicated wound care division, there is a clear entry point to target hospitals, clinics, and wound centers seeking advanced orthobiologics and regenerative solutions to enhance healing outcomes.

Autologous tech focus The emphasis on autologous and live cellular solutions indicates a buyer base prioritizing patient-sourced therapies. Sales opportunities exist with orthopedic surgeons, sports medicine centers, and regenerative medicine programs that require PRP, PRFM, and bone graft substitutes.

Product portfolio access A track record of commercial launches such as BIO-REIGN 3D and Bioincyte PRP systems demonstrates a diversified portfolio. This creates opportunities to upsell or cross-sell new platforms to current customers and to expand into adjacent musculoskeletal indications.

Growth potential Revenue in the mid single to lower double digits and active product launches indicate a growing company with available capacity for partnerships, distribution deals, and co-marketing efforts to accelerate market penetration in orthobiologics and regenerative medicine.

Similar companies to Royal Biologics, Inc.

Royal Biologics, Inc. Tech Stack

Royal Biologics, Inc. uses 8 technology products and services including LinkedIn Ads, WordPress, Salesforce, and more. Explore Royal Biologics, Inc.'s tech stack below.

Media & News

Royal Biologics, Inc.'s Email Address Formats

Royal Biologics, Inc. uses at least 2 email formats:
Royal Biologics, Inc. Email FormatsExamplePercentage
First.Last@royalbiologics.comJohn.Doe@royalbiologics.com
77%
First@royalbiologics.comJohn@royalbiologics.com
23%

Frequently Asked Questions

What is Royal Biologics, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Royal Biologics, Inc.'s official website is royalbiologics.com and has social profiles on LinkedIn.

How much revenue does Royal Biologics, Inc. generate?

Minus sign iconPlus sign icon
As of November 2026, Royal Biologics, Inc.'s annual revenue is estimated to be $10M - $25M.

What is Royal Biologics, Inc.'s SIC code and NAICS code?

Minus sign iconPlus sign icon
Royal Biologics, Inc.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Royal Biologics, Inc. have currently?

Minus sign iconPlus sign icon
As of November 2026, Royal Biologics, Inc. has approximately 27 employees across 1 continents, including North America. Key team members include Senior Supply Chain Operations Associate: T. S. Explore Royal Biologics, Inc.'s employee directory with LeadIQ.

What industry does Royal Biologics, Inc. belong to?

Minus sign iconPlus sign icon
Royal Biologics, Inc. operates in the Biotechnology Research industry.

What technology does Royal Biologics, Inc. use?

Minus sign iconPlus sign icon
Royal Biologics, Inc.'s tech stack includes LinkedIn Ads, WordPress, Salesforce, Microsoft 365, Google Cloud, Yoast SEO, HTTP/3 and MonsterInsights.

What is Royal Biologics, Inc.'s email format?

Minus sign iconPlus sign icon
Royal Biologics, Inc.'s email format typically follows the pattern of First.Last@royalbiologics.com. Find more Royal Biologics, Inc. email formats with LeadIQ.

When was Royal Biologics, Inc. founded?

Minus sign iconPlus sign icon
Royal Biologics, Inc. was founded in 2015.
Royal Biologics, Inc. logo

Royal Biologics, Inc.

Biotechnology ResearchNew Jersey, United States11-50 Employees

Royal Biologics, Inc. is a biotechnology research company focused on orthobiologics and life sciences, aiming to advance solutions that promote healing across musculoskeletal and regenerative medicine contexts. Its work centers on autologous and live cellular technologies, with products and systems designed to support enhanced healing and surgical outcomes for patients, alongside wound care applications. The company targets clinicians and healthcare providers seeking advanced therapeutic options for tissue repair and regeneration, addressing needs in orthopedic and regenerative medicine settings. Based in Hackensack, New Jersey, Royal Biologics operates within the biotechnology research sector, pursuing development and commercialization of novel biologic and biomaterial solutions. In addition to pursuing new product launches, the company has announced strategic developments such as partnerships and the commercial introduction of Derm-Maxx and related wound care offerings, reflecting an active program of expanding its clinical portfolio. }

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2015
Employees
11-50

Section iconFunding & Financials

  • $10M - $25M

    Royal Biologics, Inc.'s revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.